Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients.
Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients.
复制标题
对 65 例输血再生障碍性贫血患者进行有或无供体血沉棕黄层细胞的骨髓移植。
作者：
Rainer;Storb;Kristine;C.;Doney;E.;D.;Thomas;Fred;Appelbaum;Dean;Buckner;Reginald;A.;CIift;H.;Joachim;Deeg;Brian;W.;Goodell;Robert;Hackman;John;Hansen;Jean;Sanders;Keith;Sullivan;Paul;L.;Weiden;P.;Witherspoon
65 名患有严重再生障碍性贫血的多次输血患者接受了环磷酰胺治疗，随后移植贫血患者接受了环磷酰胺治疗，随后接受了来自 HLA 相同兄弟姐妹的移植物。评估骨髓接种后施用活供体血沉棕黄层细胞对移植物排斥和存活的影响。本文列出了 43 名接受如此治疗的患者的结果以及 22 名同时接受单独骨髓治疗的患者的结果。大多数接受血沉棕黄层治疗的患者体外致敏试验呈阳性，表明移植物排斥的风险很高，而仅接受骨髓治疗的患者中，除了一名患者外，所有患者的检测结果均呈阴性。接受骨髓和血沉棕黄层治疗的 43 名患者中有 30 名 (70%) 在移植后存活 10 至 61 个月（中位数 36 个月）； 4 人死于移植物排斥反应，6 人死于急性或慢性移植物抗宿主病 (GVHD)。 22 名仅接受骨髓移植的患者中有 11 名 (50%) 的存活时间在 29 至 65 个月之间（中位数为 52 个月）； 7 人在移植物排斥后死亡，3 人因 GVHD 死亡。与 1976 年之前移植的患者相比，在目前报道的输血患者中，在骨髓接种物中添加血沉棕黄层细胞输注降低了排斥风险，并提高了生存率。然而，慢性 GVHD 的风险增加。女性骨髓捐赠者的存活率 (73%) 略好于男性骨髓捐赠者的存活率 (58%)。
Sixty-five multiply transfused patients with severe aplastic anemia were given cyclophosphamide followed by grafts anemia were given cyclophosphamide followed by grafts from HLA-identical siblings. The effect of the administration of viable donor buffy coat cells following the marrow inoculum was evaluated with regard to graft rejection and survival. Results in 43 patients so treated are presented along with those in 22 concurrent patients given marrow alone. Most patients given buffy coat had positive in vitro tests of sensitization indicating a high risk for graft rejection, while all but one of the patients given marrow alone had negative tests. Thirty of the 43 (70%) patients given marrow and buffy coat are alive between 10 and 61 mo (median 36) after grafting; 4 died after graft rejection and 6 with acute or chronic graft-versus-host disease (GVHD). Eleven of the 22 (50%) patients given marrow alone are alive between 29 and 65 mo (median 52); 7 died after graft rejection and 3 with GVHD. The addition of buffy coat cell infusions to the marrow inoculum reduced the risk of rejection and increased survival in the currently reported transfused patients when compared to patients grafted before 1976. However, there was an increased risk of chronic GVHD. Recipients of marrow from female donors survived slightly better (73%) than recipients of male marrow (58%).
影响因子：
20.3
作者：
K. Sullivan;H. Shulman;R. Storb;Weiden Pl;R. Witherspoon;G. McDonald;M. Schubert;K. Atkinson;Thomas Ed
通讯作者：
K. Sullivan;H. Shulman;R. Storb;Weiden Pl;R. Witherspoon;G. McDonald;M. Schubert;K. Atkinson;Thomas Ed
研究再生障碍性贫血患者细胞的混合白细胞培养物对 HLA 相同同胞细胞的反应。
影响因子：
6.2
作者：
Mickelson,EM;Clift,RA;Fefer,A;Storb,R;Thomas,ED;Warren,RP;Hansen,JA
通讯作者：
Hansen,JA